+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model



Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model



Journal of Antimicrobial ChemoTherapy 58(5): 960-965



To compare in an in vitro kinetic model the pharmacodynamics of moxifloxacin and levofloxacin with a concentration-time profile simulating the human free non-protein bound concentrations of 400 mg moxifloxacin intravenous (iv) once daily, 500 mg levofloxacin iv once daily and 750 mg levofloxacin iv once daily against strains of Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli with variable susceptibility to fluoroquinolones. The strains used in the study included S. pneumoniae ATCC 6306 (native strain), S. pneumoniae 19397 (double mutation; gyrA and parC), S. pneumoniae 4241 (single mutation; parC), S. aureus ATCC 13709 (native strain), S. aureus MB5 (single mutation; gyrA), E. coli M12 (single mutation; gyrA), E. coli ATCC 25922 (native strain) and K. pneumoniae ATCC 29655 (native strain). The strains were exposed to moxifloxacin and levofloxacin in an in vitro kinetic model simulating the free human serum concentration-time profile of moxifloxacin 400 mg once daily, levofloxacin 500 mg once daily and 750 mg once daily. Repeated samples were taken regularly during 24 h and viable counts were carried out. A correlation was seen between both the area under the serum concentration curve and MIC (AUC/MIC) and the peak concentration/MIC (Cmax/MIC) versus area under the bactericidal killing curve (AUBKC) or Deltalog0-24 cfu/mL. Compiling all data, an AUC/MIC of approximately 100 and a Cmax/MIC of 10 gave a maximal bactericidal effect for both levofloxacin and moxifloxacin. In accordance with the results from others, our study indicated that a lower AUC/MIC was needed for S. pneumoniae in comparison with the Gram-negative bacteria studied. Moxifloxacin yielded higher AUC/MIC and Cmax/MIC against the investigated Gram-positive bacteria in comparison with levofloxacin 500 mg once daily and 750 mg once daily.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012878437

Download citation: RISBibTeXText

PMID: 16936293

DOI: 10.1093/jac/dkl356


Related references

Comparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae. ChemoTherapy 49(1-2): 33-35, 2003

Comparison of the Bactericidal Activity of Moxifloxacin and Levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae. Chemotherapy 49(1-2): 33-35, 2003

Bronchopulmonary pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae using an in vitro model. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 43: 17, 2003

Microbial Growth Curves Of Staphylococcus Aureus, Klebsiella Pneumoniae, Escherichia Coli, And Streptococcus Faecalis On Guinea Pig Plasma. Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales 158: 215-218, 1964

Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid. Antimicrobial Agents and ChemoTherapy 44(5): 1352-1355, 2000

Comparative pharmacodynamics of telithromycin and clarithromycin with Streptococcus pneumoniae and Staphylococcus aureus in an in vitro dynamic model: focus on clinically achievable antibiotic concentrations. International Journal of Antimicrobial Agents 26(3): 197-204, 2005

Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae. Antimicrobial Agents and ChemoTherapy 48(4): 1215-1221, 2004

Interspecies prediction of antimicrobial effects of gatifloxacin and ciprofloxacin on Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae, using an in vitro dynamic model. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 38: 7, 1998

Post-antibiotic effects of ofloxacin on Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus pyogenes. ChemoTherapy 39(4): 265-271, 1993

Post-Antibiotic Effects of Ofloxacin on Escherichia coli , Klebsiella pneumoniae , Staphylococcus aureus , and Streptococcus pyogenes. Chemotherapy 39(4): 265-271, 1993

Post-antibiotic effects of cefdinir on Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus and Streptococcus pyrogenes. Chemotherapy 40(4): 232-238, 1994

In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model. Antimicrobial Agents and ChemoTherapy 60(8): 4764-4769, 2016

Bactericidal activity of ciprofloxacin in serum and urine against Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus and Streptococcus faecalis. Journal of Antimicrobial ChemoTherapy 16(3): 341-347, 1985

Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. Journal of Antimicrobial ChemoTherapy 47(6): 811-818, 2001

Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. Clinical Infectious Diseases 32(Suppl. 1): S33, 2001